SCHEMBL26436233

SCHEMBL26436233

O=C(O)c1ccc(Nc2ccncc2)cc1C(F)(F)F

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAS2R14 Q9NYV8 4/20 0.49
SORT1 Q99523 2/20 0.44
AKR1C3 P42330 1/20 0.43
AKR1C2 P52895 1/20 0.43
UBE2N P61088 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
MEN1 O00255 1/20 0.42
GMNN O75496 1/20 0.42
ALDH1A1 P00352 1/20 0.42
LMNA P02545 1/20 0.42
TTR P02766 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
PKM P14618 1/20 0.42
NFKB1 P19838 1/20 0.42
UGT1A1 P22309 1/20 0.42
PTGS1 P23219 1/20 0.42
PTGS2 P35354 1/20 0.42
PMP22 Q01453 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26436202 0.86 CFTR (0.44) TAS2R14L3MBTL1ALDH1A1KMT2A
SCHEMBL23448650 0.78 KMT2A (0.50) AKR1C3AKR1C2MEN1ALDH1A1LMNA
SCHEMBL30828569 0.78 MAPT (0.56) L3MBTL1MEN1ALDH1A1PKMKMT2A
SCHEMBL12893520 0.75 ALDH1A1 (0.50) AKR1C3AKR1C2MEN1ALDH1A1LMNA
SCHEMBL29151820 0.74 MAPT (0.51) TAS2R14AKR1C3AKR1C2MEN1ALDH1A1
SCHEMBL14325837 0.73 CYP1A2 (0.50) TAS2R14L3MBTL1MEN1LMNACYP1A2
SCHEMBL30017034 0.72 KDM4C (0.53) SORT1L3MBTL1MEN1ALDH1A1DHODH
SCHEMBL115907 0.72 KDM4C (0.53) SORT1L3MBTL1MEN1ALDH1A1DHODH
SCHEMBL1887153 0.71 NAPRT (0.64) L3MBTL1TYK2JAK2
SCHEMBL9431654 0.71 L3MBTL1 (0.55) TAS2R14L3MBTL1MEN1CYP3A4KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230127046-A1 G9a INHIBITOR RIKEN (JP) 2023-04-27 US disclosed
US-20230127046-A1 G9a INHIBITOR RIKEN (JP) 2023-04-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230127046-A1 G9a INHIBITOR EZH2, BMI1, DOT1L TAS2R14 4303/4885SORT1 4818/4885AKR1C3 3785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.